Download Databook
Download Sample
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
June 2025
The global sex-based drug development market is emerging as a high-potential sector, set on a strong growth trajectory from 2024 to 2034. This rising momentum is fueled by growing recognition of sex-specific biological differences in drug response, shifting regulatory perspectives, and advancements in precision medicine technologies. The market is expected to generate significant revenue over the forecast period as healthcare systems increasingly prioritize personalized treatment approaches tailored to male and female physiology.
The global sex-based drug development market is experiencing significant growth due to rising awareness about sexual health, increasing focus on precision medicine based on individual sex characteristics, and growing clinical trials over diverse populations to boost the efficacy and safety of drugs. Although in the coming era, there are many opportunities such as enhanced targeted drug approaches, different preclinical and clinical studies based on sex-specific drugs, and accelerating education and awareness about sex-based concerns and drug development.
Sex-based drug development is also termed as sex-specific medicine or gender specific medicine, which acknowledges the major difference that appears in how men and women show responses to drugs and diseases. Globally, rising conditions affecting sexual health, growing awareness, and boosting demand for personalized medicines are critical factors driving the sex-based drug development market growth. There are different cases, such as varying symptoms in men and women possessing cardiovascular disease risks, which result in sex-based diagnostic and treatment plans. As well as, the market is highly emphasizing both sexes' clinical trials and controlling sex-specific subgroup analysis, which assists in the identification of robust variabilities in drug responses.
Numerous ongoing breakthroughs in the digital health sector, AI has a crucial role in the respective market as its algorithms help in the analysis of huge datasets of genomics, proteomics, and clinical data to determine patterns and anticipate drug responses based on sex. As well as in the development of tailored drug dosages and treatment strategies for individual cases, considering their gender and else factors to improve efficacy and reduce side effects, AI plays a majorly role, which ultimately impacts the market expansion. Also, AI enables the estimation of probable safety concerns and toxicity risks in particular populations based on sex.
Increasing Approaches in Drug Development Based on Sex Differences
As men and women have having wide range of biological variations, such as in genetics (X and Y sex chromosomes), sex hormones (Estrogen and testosterone), and metabolism, which are highly affected in the anatomical and physiological concepts, which require treatment based on sex and all these factors. Ultimately, in the sex-based drug development market, several differences in the men and women in their pharmacokinetics, pharmacodynamics, and adverse drug reactions demand dosage adjustments and drugs with greater efficacy, novel drug development based on sex-specific.
Limitations in Historical Concerns and Regulatory Considerations
In clinical trials, historically, there were several demerits, such as childbearing women were excluded from early trials as they could affect the developing fetus due to rising concerns of possible adverse effects on the same. This results in limited data to researchers on how drug impacting based on sex in women compared to men. Also, the FDA has described certain factors to highlight these concerns, such as the lifting limitations on including women in prior trials and enhancing the need for data analysis by sex.
Escalating Sex-specific Research and Personalized Medicine Approaches
Nowadays, in the sex-based drug development market, there are a number of opportunities rising, like performing preclinical research employing both men and women models, and embracing female-specific cell lines and conditions, which helps detect based-on sex differences in drug responses. However, it has a major role in the development of sex-specific dosing, which addresses the metabolism and elimination in sex differences, along with based-on sex different conditions primarily in women, such as endometriosis and polycystic ovary syndrome, demand for personalized treatments with raised efficacy, minimized side effects, and enhanced outcomes.
By gender, the men segment held a dominant revenue share of the market in 2024, due to the different anatomical and physiological factors. Men typically possess a greater basal metabolic rate because of their lean body mass or muscle tissue as compared to women, which overall impacts drug metabolism and elimination in the body based on sex. Along with this, the testosterone hormone in men is a vital factor contributing to several physiological processes, which may affect pharmacodynamics, i.e., drug responses in men.
By gender, the women segment is expected to grow fastest during the forecast period. Due to factors like lower body weight, higher body fat percentage, and various hormone profiles in women can play a crucial role in the pharmacokinetic and pharmacodynamic properties of the drug and the body. This may result in higher drug concentrations and extended durations of action in women compared with men. Also, hormones in women, estrogen and progesterone are widely affect the liver enzymes' activity in the metabolism of drugs, leading to a major impact on drug elimination.
By drug type, the estrogen therapy segment led by capturing a major revenue share of the sex-based drug development market. This segment is impacted by its vital role in medical transition for transgender women, which enables feminizing changes and suppresses male secondary sex characteristics. Besides this, this hormone can alter the growth hormone axis and production of insulin-like growth factor (IGF-1), which makes a significant contribution to the development of muscle and bone.
By drug type, the flibanserin segment is expected to grow fastest in the coming years. The flibanserin helps to discover an underserved area in women’s sexual health, enabling a pharmacological choice for HSDD. Moreover, as it targets the brain’s neurotransmitter system, instead of aiming to address hormonal disturbances, it offers a unique approach to treat HSDD. Also, this has robust efficacy and safety properties, which are developed from clinical trials, particularly created for women with HSDD.
By disease, the dyspareunia segment led the market in 2024, due to the rising awareness of sexual health concerns and the increasing cases of vulvar and vaginal atrophy, results in dyspareunia. The sex-based drug development market is experiencing dominance of this segment as a growing development of new drugs and treatments to treat dyspareunia, especially in conditions such as endometriosis.
By disease, the HSDD segment is expected to grow fastest during the forecast period. The hypoactive sexual desire disorder (HSDD) segment is propelled by accelerating awareness about it, boosting physiological conditions including anxiety and depression, and a rising recognition of its neurological basis. Moreover, these neurological conditions can be demonstrated by reduced libido, emphasizing the overall demand for HSDD treatments.
By route of administration, the parenteral segment held the major revenue share of the market in 2024. Factors such as protein-based and parenteral routes, including intravenous (IV) injection, are a broadly efficacious way to deliver them, bypassing first-pass metabolism and ensuring faster systemic bioavailability. As well as differences in men and women based on sex, like hormones, body compositions, and metabolic variations, are impacting efficacy and toxicity, particularly systemic delivery through parenteral routes.
By route of administration, the topical segment is expected to grow at the fastest CAGR over the projected period. As a topical delivery approach has several advantages like targeted treatments in which it supports in delivering high local concentrations of drug at the site of action, reduces exposure to other body tissues, and being one of the easiest way to patients with raised convenience, non-invasive and less systemic exposure compared to IV and oral routes.
By distribution channel, the hospital pharmacies segment dominated by contributing a major share of the sex-based drug development market in 2024. Primarily, the hospital pharmacies have specific treatment for female sexual dysfunction (FSD). Along with this, a rising number of visits to the hospital for FSD, growing access to the same treatment drugs, and the widespread demand for sex-customized regimens.
By distribution channel, the online pharmacies segment is expected to grow fastest in the upcoming years. Majorly contributing factors are cost-effectiveness, one of the convenient and easily accessible ways, and rising patients' preference for the respective approach. Also, in the 2025 era, broad populations are adopting digital health, like online consultations and telemedicine are significantly contributing to the overall expansion of the sex-based drug development market.
North America led the market in 2024. Due to the increasing regulatory requirements, particularly in women's clinical trials and sex-based analysis of results, progressing research activities that address the several sex-specific differences related to biological properties, such as pharmacodynamics, and other factors. Also, the rising adoption of personalized medicines related to patient-specific characteristics is contributing critically to the market growth.
The market is driven by the growing awareness about sex related concerns, guidelines, and policies of regulatory bodies like the FDA, which increases its significance in the sex-based drug development approaches. Also, the accelerating research, which emphasizes novel development of personalized medicines, including sex and other factors.
Canada has taken initiatives in health to support sex and gender-based analysis plus (SGBA+) in drug regulation and policy, with advancements in research on mechanisms of disease and drug action based on sex. Moreover, growing call for more diverse clinical trials for rising populations.
In ASAP, the region is expected to grow fastest in the studied years. As ASAP is experiencing numerous public health challenges, such as growing cases of HIV, STIs, and substance abuse, demand for advanced treatment approaches and fueling the market growth. Besides this, the ethical and legal frameworks are widely considered to have access to healthcare, such as the development of safe and effective drugs for all populations, regardless of their gender.
China has been experiencing lucrative growth driven by the increasing investments in research into sex-specific drug development, both locally and through international partnerships. These fundings enable studies on different factors of drug response, like those related to particular diseases, drug classes, and patient populations.
In India, escalating recognition about women's and men experience health outcomes, and describing the needs of diverse populations, with promoting equality in healthcare access. This kind of development supports in development of personalized treatments. Also, as novel advancements have various benefits over traditional drug development, they result in the expansion of the market.
Europe, with significant growth in the market, is widely focusing on understanding and highlighting variance in drug response and effects in men and women, with a rising emphasis on including sex as a biological variable in the drug development process. However, the boosting technological advancements in genomic sequencing, proteomics, and other omics technologies are enabling the detection of sex-specific molecular mechanisms that inform drug development.
Germany has taken major steps in sex-based drug development in different sectors, like cardiovascular disease, neurological disorders, and infectious conditions. Also, there are many ongoing research is exploring the difficult interplay between sex, gender, and drug response, resulting in highly personalized and efficient treatments.
In the UK, focused on signaling molecules which play a major role in cell growth and development, ultimately robust targets for sex-based therapies. As well as, the government of the UK is increasingly encouraging research and data collection by sex in drug development.
In February 2025, the Australian government announced its investment of $573.3 million to build Australia’s future and boost Medicare to deliver more options, affordable and better healthcare for women. Minister Gallagher stated that this investment has taken on the women's initiative to the government to take their healthcare seriously, with various advantages such as cost effectiveness, and robust healthcare. (Source- Australian Government)
By Gender
By Drug Type
By Disease
By Route of Administration
By Distribution Channel
By Region
June 2025
June 2025
June 2025
June 2025